NCT01432353View on ClinicalTrials.gov

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

DFRF4539A

multiple ascending doses

Trial Locations (8)

10021

New York

20817

Bethesda

32224

Jacksonville

34232

Sarasota

37203

Nashville

60611

Chicago

85259

Scottsdale

91010

Duarte

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY